三级aa视频在线观看-三级国产-三级国产精品一区二区-三级国产三级在线-三级国产在线

US EUROPE AFRICA ASIA 中文
Business / Companies

GSK puts China corruption case behind it, forms new business model

By Cecily Liu (chinadaily.com.cn) Updated: 2015-10-22 20:17

GSK puts China corruption case behind it, forms new business model

The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai in this July 12, 2013 file photo.[Photo/Agencies]

GlaxoSmithKline emerged from its corruption scandal in China in 2013 to form a new business model in the country and is committed to further expansion there, chief executive officer Andrew Witty told China Daily in London on Wednesday in an exclusive interview.

"We think it's a very sad and disappointing experience, but we've reacted constructively and learnt many things. And now we understand China better, we have a new commercial model and incentive system, which is in step with the expectations of the Chinese government," Witty said.

In 2013, GSK was found by the Chinese authorities to be bribing doctors to prescribe its drugs to patients, and after a court trial the company was made to pay a $489 million fine in 2014.

Witty said that GSK has since developed a commercial model with improved technology and transparency.

The transparency of the model allows GSK to monitor its sales staff to make sure no bribe is paid to doctors, and the continuously improving technology allows doctors to obtain much more information about GSK drugs to aid their decision making process when prescribing medicine.

"We've made it clear to the doctors in China about our changes and have spent a great deal of time to explain to them the reasons for us making the changes. We have received a lot of understanding and appreciation from doctors about our approach," Witty said.

As well, GSK has invested in continuously improving technology to reduce the cost of the medicine, Witty said.

Speaking about China's healthcare market environment, Witty said that China is a country that it takes time to understand, just like any other country, and understanding China encompasses its economic policies, economic direction and regulation.

He said that "GSK is lucky to be a guest of China" and will fulfill its responsibility to deliver the medicine that are up to expectations.

GSK also announced on Wednesday that it will invest 2 million pounds in a 3 year partnership with the National Health and Family Planning Commission of China to train seven thousand Chinese doctors in the diagnosis and treatment of Hepatitis B.

Witty said that this investment reaffirms GSK's long term commitment to serving China and the healthcare needs of patients in the country.

Hepatitis B is a high priority in China, with about 20 million sufferers across the country remaining untreated.

"We think it is important that we're doing the training in partnership with the Chinese government, so that we can make sure what we have invested in will help to address issues that are of real importance to China," said Witty.

He said that the Hepatitis B investment is similar to GSK's investment into training Chinese doctors in the treatment of respiratory conditions and chronic obstructive pulmonary disease, announced last month, which are also healthcare priority areas identified by the government.

The Hepatitis B program, to be run over three years, and delivered by the Development Center for Medical Science and Technology, National Health and Family planning Commission of China, will help doctors understand how to diagnose, treat and provide ongoing management to patients with Hepatitis B.

Witty said that China will remain important to GSK over the long term, in particular because it has a large population, meaning that from a commercial perspective the sales potential is great, and from a research perspective it can provide a valuable environment to develop medicine that GSK can use globally.

GSK was ranked as the world's sixth-largest pharmaceutical company in 2014, with revenue of 23 billion pounds.

GSK has already committed 6 million pounds for public health initiatives in China over the next five years, with around 4 million being spent on independent GP training, the company said in a statement.

To contact the reporter: cecily.liu@mail.chinadailyuk.com

Hot Topics

Editor's Picks
...
主站蜘蛛池模板: 国产一级一级毛片 | 久久2| 国产伦精品一区二区三区免 | 亚洲欧美一区二区久久香蕉 | 日韩免费一区 | 久久最新网址 | 国产成人精品一区二区免费 | 亚洲 欧美 中文字幕 | 成人精品网| 综合 欧美 国产 视频二区 | 黄色小视频免费看 | 九九精品免视看国产成人 | 午夜一级毛片免费视频 | 男人的天堂久久精品激情 | 国产精品国产高清国产专区 | 天干天干天啪啪夜爽爽99 | 人人草人人草 | 欧美一级色片 | 欧美专区一区二区三区 | 东京道一本热大交乱 | 好爽~好硬~好紧~蜜芽 | 日本一区二区三区精品视频 | 成人午夜免费在线观看 | 国产草莓视频入口免费网站 | 亚洲欧美色欧另类欧 | 一区二区在线免费视频 | 国产精品免费视频一区二区 | 国内免费自拍视频 | 成人久久网 | 午夜毛片不卡高清免费 | 黄色电影毛片 | 一区二区三区网站在线免费线观看 | 日本欧美高清 | 欧美成人综合在线观看视频 | 黄短视频在线观看免费版 | 国产精品美女久久久久久 | 99精品国产自产在线观看 | 在线观看国产精品日本不卡网 | 精品国产一区二区三区久久 | 日韩欧美一区二区三区免费观看 | 国产一区二区三区精品久久呦 |